期刊
NEUROBIOLOGY OF AGING
卷 35, 期 3, 页码 576-584出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2013.09.028
关键词
Alzheimer's disease; Amyloid imaging; Cognitive function; Glucose metabolism; AD risk
资金
- NIA [AG021155, AG027161, P50 AG033514]
- Veterans Administration Merit Review Grant [I01CX000165]
- Clinical and Translational Science Award [UL1RR025011]
- Helen Bader Foundation
- Northwestern Mutual Foundation
- Extendicare Foundation
- Veterans Administration
- Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison, WI
- [P50 HD03352]
To determine the relationship between amyloid burden and neural function in healthy adults at risk for Alzheimer's Disease (AD), we used multimodal imaging with [C-11]Pittsburgh compound B positron emission tomography, [F-18]fluorodeoxyglucose, positron emission tomography, and magnetic resonance imaging, together with cognitive measurement in 201 subjects (mean age, 60.1 years; range, 46 -73 years) from the Wisconsin Registry for Alzheimer's Prevention. Using a qualitative rating, 18% of the samples were strongly positive Beta-amyloid (A beta+), 41% indeterminate (A beta i), and 41% negative (A beta-). A beta+ was associated with older age, female sex, and showed trends for maternal family history of AD and APOE4. Relative to the A beta group, A beta(vertical bar) and A beta i participants had increased glucose metabolism in the bilateral thalamus; A beta+ participants also had increased metabolism in the bilateral superior temporal gyrus. A beta+ participants exhibited increased gray matter in the lateral parietal lobe bilaterally relative to the A beta- group, and no areas of significant atrophy. Cognitive performance and self report cognitive and affective symptoms did not differ between groups. Amyloid burden can be identified in adults at a mean age of 60 years and is accompanied by glucometabolic increases in specific areas, but not atrophy or cognitive loss. This asymptomatic stage may be an opportune window for intervention to prevent progression to symptomatic AD. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据